Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

53 Biggest Movers From Friday

By Lisa Levin
September 7, 4:58 AM
Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform.

ADGI

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights
September 3, 1:58 PM
Gainers

APOP

Read More
3 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

35 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin
September 3, 12:01 PM
Gainers

ADXS

Read More
22 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For July 29, 2021

By Benzinga Insights
July 29, 4:23 AM
  Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

AB

Read More
5 minute read
  • Biotech
  • Earnings
  • FDA
  • IPOs
  • News
  • Penny Stocks
  • Small Cap
  • Top Stories

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline
July 25, 9:26 AM
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

61 Biggest Movers From Yesterday

By Lisa Levin
July 23, 5:18 AM
Gainers

ABSI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

JMP Securities Maintains Market Outperform on Evelo Biosciences, Raises Price Target to $38

By Benzinga Newsdesk
June 23, 2:00 PM
JMP Securities analyst Gobind Singh maintains Evelo Biosciences (NASDAQ:EVLO) with a Market Outperform and raises the price target from $36 to $38.

EVLO

Read More
8 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For June 23, 2021

By Benzinga Insights
June 23, 10:04 AM
 

ACHV

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Cantor Fitzgerald Initiates Coverage On Evelo Biosciences with Overweight Rating, Announces Price Target of $28

By Benzinga Newsdesk
June 23, 7:51 AM
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Evelo Biosciences (NASDAQ:EVLO) with a Overweight rating and announces Price Target of $28.

EVLO

Read More
1 minute read
  • FDA
  • News

Evelo Biosciences Publishes Study Titled ‘EDP1867 Phase 1a/1b Study in Healthy Participants and Participants With Moderate Atopic Dermatitis and, Optionally, Moderate Psoriasis, and/or Mild Asthma’ To ClinicalTrials.Gov Site

By Benzinga Newsdesk
June 15, 1:07 PM
https://clinicaltrials.gov/ct2/show/NCT04927195

EVLO

Posts navigation

Previous 1 … 7 8 9 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service